Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,386 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.
Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, Jackson E, Kelcz F, Yeh BM, Lee FT Jr, Charnsangavej C, Park JW, Ashton EA, Steinfeldt HM, Pithavala YK, Reich SD, Herbst RS. Liu G, et al. Among authors: jackson e. J Clin Oncol. 2005 Aug 20;23(24):5464-73. doi: 10.1200/JCO.2005.04.143. Epub 2005 Jul 18. J Clin Oncol. 2005. PMID: 16027440 Clinical Trial.
Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.
Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, Rasmussen E, Sun YN, Zhong D, Hwang YC, Evelhoch JL, Oliner JD, Le N, Rosen LS. Herbst RS, et al. Among authors: jackson e. J Clin Oncol. 2009 Jul 20;27(21):3557-65. doi: 10.1200/JCO.2008.19.6683. Epub 2009 Jun 22. J Clin Oncol. 2009. PMID: 19546406 Clinical Trial.
A phase I surrogate endpoint study of SU6668 in patients with solid tumors.
Xiong HQ, Herbst R, Faria SC, Scholz C, Davis D, Jackson EF, Madden T, McConkey D, Hicks M, Hess K, Charnsangavej CA, Abbruzzese JL. Xiong HQ, et al. Invest New Drugs. 2004 Nov;22(4):459-66. doi: 10.1023/B:DRUG.0000036688.96453.8d. Invest New Drugs. 2004. PMID: 15292716 Clinical Trial.
Quantitative magnetic resonance imaging phantoms: A review and the need for a system phantom.
Keenan KE, Ainslie M, Barker AJ, Boss MA, Cecil KM, Charles C, Chenevert TL, Clarke L, Evelhoch JL, Finn P, Gembris D, Gunter JL, Hill DLG, Jack CR Jr, Jackson EF, Liu G, Russek SE, Sharma SD, Steckner M, Stupic KF, Trzasko JD, Yuan C, Zheng J. Keenan KE, et al. Among authors: jackson ef. Magn Reson Med. 2018 Jan;79(1):48-61. doi: 10.1002/mrm.26982. Epub 2017 Oct 30. Magn Reson Med. 2018. PMID: 29083101 Free article. Review.
A standard system phantom for magnetic resonance imaging.
Stupic KF, Ainslie M, Boss MA, Charles C, Dienstfrey AM, Evelhoch JL, Finn P, Gimbutas Z, Gunter JL, Hill DLG, Jack CR, Jackson EF, Karaulanov T, Keenan KE, Liu G, Martin MN, Prasad PV, Rentz NS, Yuan C, Russek SE. Stupic KF, et al. Among authors: jackson ef. Magn Reson Med. 2021 Sep;86(3):1194-1211. doi: 10.1002/mrm.28779. Epub 2021 Apr 13. Magn Reson Med. 2021. PMID: 33847012 Free PMC article.
Dependence of DCE-MRI biomarker values on analysis algorithm.
Ng CS, Wei W, Bankson JA, Ravoori MK, Han L, Brammer DW, Klumpp S, Waterton JC, Jackson EF. Ng CS, et al. PLoS One. 2015 Jul 24;10(7):e0130168. doi: 10.1371/journal.pone.0130168. eCollection 2015. PLoS One. 2015. PMID: 26208254 Free PMC article.
Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab.
Falchook GS, Wheler JJ, Naing A, Jackson EF, Janku F, Hong D, Ng CS, Tannir NM, Lawhorn KN, Huang M, Angelo LS, Vishwamitra D, Hess K, Howard AN, Parkhurst KL, Amin HM, Kurzrock R. Falchook GS, et al. Oncotarget. 2014 Nov 15;5(21):10280-92. doi: 10.18632/oncotarget.2163. Oncotarget. 2014. PMID: 25373733 Free PMC article. Clinical Trial.
2,386 results